Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients.
Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients.
复制标题
DOI：
10.1186/1756-0500-5-65
复制
发表时间：
2012-01-24
影响因子：
1.8
通讯作者：
Liu S
中科院分区：
文献类型：
--
作者：
Mhawech-Fauceglia P;Wang D;Lele S;Frederick PJ;Pejovic T;Liu S
转移是癌症死亡的主要原因，是一个多步骤的过程。Moesin （MSN）是ezrin-rdixin-moesin家族的成员，Claudin7 （CLDN7）是一种紧密连接蛋白，它们都在肿瘤细胞转移中发挥作用。在此之前，我们发现与子宫内膜样腺癌相比，子宫浆液性癌中MSN mRNA水平过表达，而CLDN7 mRNA水平过表达。本研究的目的是检测MSN和CLDN7蛋白在子宫内膜癌（EC）中的表达，并评估其预后价值。从档案中检索到265例EC患者。组织石蜡切片进行MSN和CLDN7免疫染色。报告每种抗体的表达，然后与临床病理预后因素相关，包括年龄、肿瘤分级、肿瘤分期、淋巴血管受累、肌层浸润深度、总生存期（OS）、无病生存期（DFS）和疾病死亡（DOD）。MSN和CLDN分别占总病例的46%和52%。我们观察到MSN+染色与肿瘤分级、浆液细胞癌和透明细胞癌亚型之间的相关性（p < 0.001）。CLDN7+染色与低肿瘤分级和子宫内膜样腺癌亚型有相关性（p分别< 0.001和0.001）。然而，没有发现MSN和CLDN7表达与预后（包括OS、DOD和DFS）之间的关联。MSN和CLDN7在预测EC患者疾病结局方面的显著预后价值尚未得到证实。然而，MSN和CLDN7免疫表达的EC病例的高比例及其与肿瘤分级和亚型的关联表明，这些蛋白可能在子宫内膜腺癌的肿瘤发生中发挥作用。未来的研究需要阐明它们在EC细胞中的机制特性。
Metastasis is the main cause of death in cancer and is a multistep process. Moesin (MSN), a member of the ezrin-rdixin-moesin family and Claudin7 (CLDN7), a tight junction protein, both play a role in tumor cell metastasis. Previously, we found an over-expression of MSN and under-expression of CLDN7 at the mRNA level in uterine serous carcinoma in comparison to uterine endometrioid adenocarcinoma. The purpose of this study is to determine the protein expression of MSN and CLDN7 in endometrial cancer (EC) and to evaluate their prognostic value. Two hundred sixty-five patients with EC were retrieved from the archives. MSN and CLDN7 immunostaining were performed on the tissue paraffin sections. The expression of each antibody was reported and then correlated with clinicopathological prognostic factors including age, tumor grade, tumor stage, lympho-vascular involvement, depth of myometrial invasion, overall survival (OS), disease free survival (DFS) and death of disease (DOD). MSN and CLDN were expressed in 46% and 52% of overall cases. We observed an association between MSN+ staining and tumor grade, and serous and clear cell carcinoma subtypes (p < 0.001 each). There was an association between CLDN7+ staining and low tumor grade and endometrioid adenocarcinoma subtype (p < 0.001 and 0.001 respectively). However, no association between MSN and CLDN7 expression and outcome including OS, DOD, and DFS was found. A significant prognostic value of MSN and CLDN7 in predicting disease outcomes in patients with EC was not demonstrated. Nevertheless, the high percentage of EC cases with MSN and CLDN7 immunoexpression, and their association with tumor grade and subtypes, suggests that these proteins might play a role in tumorigenesis of endometrial adenocarcinomas. Future studies are needed to shed light on their mechanistic properties in EC cells.